Navigation Links
Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine
Date:7/31/2014

ts of which were recently published in the journal Human Vaccines & Immunotherapeutics.

HPV-023

For this study (HPV-023), participants from Brazil were invited to continue follow-up. 437 women from five centers participated in this 36-month long-term follow-up for 113 months (9.4 years). The aim of the study was to evaluate efficacy against HPV-16/18 infection and associated cyto-histopathological abnormalities, persistence of immunogenicity, and safety of the vaccine. During HPV-023, anti-HPV-16/18 antibodies were measured annually by enzyme-linked immunosorbent assay (ELISA) and pseudovirion-based neutralisation assay (PBNA). Cervical samples were tested for HPV DNA every 6 months, and cyto-pathological examinations were performed annually.

Efficacy against HPV-16/18 infections

During HPV-023, no new HPV-16/18-associated infections or cyto-histopathological abnormalities occurred in the vaccine group. In particular, VE against HPV-16/18 incident infection was 100%. VE was 95.6% against incident infection over 9.4 years. Looking at secondary endpoints, the data showed no cases of either 6- or 12-month HPV-16/18 persistent infection in the vaccine group, versus four cases and one case, respectively, in the placebo group during the 26-months follow-up.

Efficacy against cyto-histopathological abnormalities

VE against cyto-histopathological abnormalities was another secondary endpoint of the study. VE was 97.1% against atypical squamous cells of undetermined significance (ASC-US), 95% against low-grade squamous intraepithelial lesion (LISL), and 100% against cervical intraepithelial neoplasia grade 1 (CIN1+) and grade 2 (CIN2+) associated with HPV-16/18.

Immunogenicity

All vaccines remained seropositive to HPV-16/18, with antibody titers remaining several folds above natural infection
'/>"/>

Contact: Andrew Thompson
andrew@landesbioscience.com
Landes Bioscience
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UGA study finds theres not always safety in numbers when it comes to extinction risk
2. Sensitive test helps improve vaccine safety
3. NIH funds development of tissue chips to help predict drug safety
4. Jeff Crandall Honored With SAE International Arnold W. Siegel International Transportation Safety Award
5. INTEGRIS Health Puts Patient Safety in the Palm of Your Hand
6. Questions about biosafety? Ask a biosafety expert
7. Climate change impacts to US coasts threaten public health, safety and economy
8. Masked mold toxins in food should be included in safety regulations
9. Additional research must be done to ensure safety of pit latrines, new study says
10. Revolutionary Face Recognition Media Exploitation System Now Available to Enhance Public Safety in Europe
11. RNA-interference pesticides will need special safety testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2015)... --  Tute Genomics , pioneer in affordable, accurate and ... company PrimBio Research Institute to be its ... interpretation. PrimBio, a certified Life Technologies Ampliseq ... to support the work of experts on the front ... of exome sequencing services: 1) Targeted Exome and 2) ...
(Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
(Date:2/25/2015)... LITTLE ROCK, Ark. , Feb. 25, 2015 ... of software and billing in the Health and ... software as well as to MYiCLUBonline.  The latest ... MYiCLUBonline and the inclusion of cardless check-in via ... demonstrated for the first time through interactive displays ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... Quebec City, September 12, 2011A study presented today by ... Medicine currently underway in Quebec City revealed that the risk ... which at least one member is an insomniac. ... Universit Laval,s School of Psychology, came to these conclusions following ...
... Findings, published today in Nature and Nature ... Genome-Wide Association Studies represent a major advance in our understanding ... potential therapeutic targets for prevention of heart disease and stroke ... published in Nature and co-led by scientists from ...
... time, USC scientists have mapped out a neuroreceptor. This ... used to treat ailments such as Alzheimer,s disease and ... images of the α7 (Alpha 7) receptor, a molecule ... regions of the brain believed to be associated with ...
Cached Biology News:Discovery of blood pressure genes could help prevent cardiovascular disease 2Discovery of blood pressure genes could help prevent cardiovascular disease 3USC scientists generate first detailed map of human neuroreceptor 2
(Date:3/26/2015)... PRC Clinical, a Silicon-Valley based ... and executive appointments effective immediately. , Mike Catelani will ... member of the Board of Directors. Daniel Head is ... Dowden will assume the position of Senior Director of ... Officer (COO), has been appointed to the position of ...
(Date:3/26/2015)... The Market Element LLC, a leading ... with Designing Gig LLC to provide website design, development, ... “Forging this alliance with Designing Gig represents a pivotal ... a comprehensive, end-to-end, digital solution for our clients, which ... Chuck Miller, president of The Market Element. “For small ...
(Date:3/26/2015)... LEXINGTON, Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ... announced a three-year, broad research collaboration for rare ... and develop novel therapies to treat rare diseases ... and commercialization capabilities with Cincinnati Children,s research expertise. ...
(Date:3/26/2015)... , March 26, 2015 ... a global clinical research organization , ... a definitive agreement to acquire all of ... ("QSI"), a leading provider of specialized pharmacovigilance ... to the collection, detection, assessment, monitoring, and ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... IRVING, Texas, Oct. 23 /PRNewswire-FirstCall/ -. Carrington,Laboratories, Inc. ... and raw material products, announced today that it,received ... are now being,traded on the OTC Bulletin Board ... market makers. The OTC Bulletin Board is ...
... N.J., Oct. 23 Collagen Matrix, Inc.,announces the ... orthopedic,and spine applications. OssiMend is an all-natural mineral-collagen,composite ... marrow,is used to fill bony voids or gaps ... OssiMend is conformable, non-friable, has a high,absorption capacity, ...
... Capital Joins Flagship Ventures Backing Leader in Fluorescence In ... ... VisEn Medical, Inc., a leader in,fluorescence in vivo imaging from ... Merck Capital Ventures,joined Flagship Ventures to co-lead this $7 million investment ...
Cached Biology Technology:Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB 2Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications 2VisEn Medical Raises $7 Million in Series B Financing 2VisEn Medical Raises $7 Million in Series B Financing 3
...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... power supply (Cat. No. Minis 150VS) is ... meet most electrophoresis needs in a personal, ... 150V power supply is capable of running ... designed for individuals to have his/her own ...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: